Article Sidebar

PDF
Date Published: 13/03/2022
Abstract Views: 547
Views PDF: 415
DOI: https://doi.org/10.51298/vmj.v510i2.2025
Issue
Vol. 510 No. 2 (2022)
Section
Các bài báo
How to Cite
Thu Hương, K. ., Hồng Minh, L. ., Hoài Thanh Vân, P. ., & Thị Tuyết Mai, K. . (2022). COST – EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN IN TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION: A SYSTEMATIC REVIEW. Vietnam Medical Journal, 510(2). https://doi.org/10.51298/vmj.v510i2.2025

COST – EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN IN TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION: A SYSTEMATIC REVIEW

Kiều Thu Hương1, Lê Hồng Minh2, Phạm Hoài Thanh Vân3, Kiều Thị Tuyết Mai1,
1 Hanoi University of Pharmacy
2 Health Economics Research and Assessment Center
3 AstraZeneca Vietnam Company Limited

Main Article Content

Abstract

Heart failure is one of major health problems, which may lead to reduce quality of life and increase risk of hospitalizations and cardiovascular death. This study was conducted to review economic evaluations of dapagliflozin in treatment of heart failure with reduced ejection fraction (HFrEF). A systematic search in Pubmed was made up. Six studies were eligible for  inclusive and exclusive criteria. In conclusion, dapagliflozin was suggested as a cost – effective treatment for HFrEF patients

Article Details

Keywords

dapagliflozin, cost – effective, heart failure with reduced ejection fraction (HFrEF)

References

1. Houck P., Dandapantula H. et al. (2020), "Cost to Save a Life in Heart Failure: Health Disparity Costs Lives", Cureus. 12 (8), pp. e10081.
2. Husereau D., Drummond M. et al. (2013), "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement", Value Health. 16 (2), pp. e1-5.
3. Krittayaphong R. , Permsuwan U. (2021), "Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction", Int J Cardiol. 322, pp. 183-190.
4. McDonagh T. A., Metra M. et al. (2021), "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure", Eur Heart J.
5. McEwan P., Darlington O. et al. (2020), "Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF", Eur J Heart Fail. 22 (11), pp. 2147-2156.
6. McEwan P., Morgan A. R. et al. (2020), "The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial", Diabetes Obes Metab.
7. McMurray J. J. V., Solomon S. D. et al. (2019), "Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction", N Engl J Med. 381 (21), pp. 1995-2008.
8. Ponikowski P., Voors A. A. et al. (2016), "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC", Eur J Heart Fail. 18 (8), pp. 891-975.
9. Savarese G. , Lund L. H. (2017), "Global Public Health Burden of Heart Failure", Card Fail Rev. 3 (1), pp. 7-11.